TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

31 citing papers in PubMed.

1. Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates.Acta pharmaceutica Sinica. B · 2026
   Review
2. Pre-existing cell states predict resistance to multiple treatments.Cell genomics · 2026
   Article
3. The Lysosome-Cathepsin Axis in Pancreatic Cancer: Mechanisms of Stromal Remodeling, Immune Evasion, and Therapy Resistance.Biomolecules · 2026
   Review
4. Decoding Drug Resistance in Pancreatic Cancer: A Subcellular Structure Perspective.Biology · 2026
   Review
5. Multi-Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma.Cancer medicine · 2026
   Article
6. p53 increases phospholipid headgroup scavenging in senescence.Nature cell biology · 2026
   Article
7. tRNA mMolecular cancer · 2026
   Article
8. Design and validation of a reporter mouse to study the dynamic regulation of TFEB and TFE3 activity throughAutophagy · 2024
   Article
9. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.Molecular biology reports · 2023
   Review
10. Impaired mitophagosome-lysosome fusion mediates olanzapine-induced aging.Aging cell · 2023
    Article
11. Ectopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion.Cell reports · 2023
    Article
12. A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer.Acta pharmacologica Sinica · 2023
    Review
13. Transcriptional regulation of autophagy and its implications in human disease.Cell death and differentiation · 2023
    Review
14. Gemcitabine promotes autophagy and lysosomal function through ERK- and TFEB-dependent mechanisms.Cell death discovery · 2023
    Article
15. Prognostic Lysosome-Related Biomarkers for Predicting Drug Candidates in Hepatocellular Carcinoma: An Insilco Analysis.Journal of hepatocellular carcinoma · 2023
    Article
16. Regulation of Aging and Longevity by Ion Channels and Transporters.Cells · 2022
    Review
17. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?Life (Basel, Switzerland) · 2022
    Review
18. Lysosome-mediated chemoresistance in acute myeloid leukemia.Cancer drug resistance (Alhambra, Calif.) · 2022
    Review
19. Defects of Nutrient Signaling and Autophagy in Neurodegeneration.Frontiers in cell and developmental biology · 2022
    Review
20. The lysosome as an imperative regulator of autophagy and cell death.Cellular and molecular life sciences : CMLS · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

13 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as